See what’s coming to on3
ON3 is a complete next-generation lifestyle hub located right in the heart of the Northeast’s thriving life science corridor, making it easy for today’s research, technology and knowledge-based organizations to easily access top talent. Companies located at ON3 will have no problem attracting top talent with both the amenities proposed on campus as well as the vibrant offerings of the Route 3 corridor and Clifton and Nutley town centers nearby. Just nine miles from the Lincoln Tunnel, geographically, the ON3 redevelopment is the closest project of its kind to New York City, close to world-class concerts, entertainment and sporting events.
With the proposed well-balanced mix of uses, the ON3 redevelopment will effortlessly blend the urban and suburban for the ultimate environment to live, work, learn and play—all right here ON3!
To learn more or inquire about leasing, please visit:
ON3 has already secured an outstanding long-term anchor and is attracting a variety of best-in-class corporate users for space we are now leasing. A seamless integration of an appropriate mix of uses - that will eventually feature medical, research, housing, retail, a hotel and much more- will ensure the campus’ longevity for decades to come.
These are ON3's current signed tenants:
SETON HALL-HACKENSACK MERIDIAN GRADUATE SCHOOL OF MEDICINE
Seton Hall University and Hackensack-Meridian Health System formed a partnership and signed a long-term lease agreement at ON3 in 2016 for a new health and medical sciences campus consisting of 16 acres and two state-of-the-art buildings on the former Hoffmann-La Roche site.
This flagship project will create the Seton Hall-Hackensack Meridian Graduate School of Medicine, which is the first private medical school built in New Jersey in decades. The new medical school, slated to open in 2018, is expected to provide a significant economic boost to the region and help curb the critical physician shortage that New Jersey and the nation currently face. In addition to the school of medicine, ON3 will become home to Seton Hall's College of Nursing and School of Health and Medical Sciences.
Modern Meadow is relocating its headquarters to ON3 at 111 Ideation Way in Nutley. Renovations are currently under way, and the development is expected to be completed by the end of 2019.
Modern Meadow uses design, biology and engineering for sustainable manufacturing. This innovative company is building high-performing, biological materials of the 21st Century. Growing leather without an animal might seem futuristic but Modern Meadow is making it reality. Biofabrication enables the company to grow nature’s materials using living cells instead of animals. Modern Meadow grows collagen, a protein found in animal skin, from which a biofabricated leather material is created.
RALPH LAUREN CORPORATION
The international fashion giant, has signed a full-building lease with ON3. The company will occupy 225,000 sq. feet of the building 100 Metro. In November of 2017, the New Jersey Economic Development Authority a 10-year, $33.1 million Grow NJ credit to make capital investments and locate in ON3 campus. The move keeps 500 jobs in the state and will need to create 200 more if the company wants the complete award.
Prism Capital Partners will immediately launch a renovation of the seven-story building, highlighted by a complete lobby redesign featuring 30-foot ceilings and a new entryway. Outside, the firm will create a courtyard with communal areas for social and business gatherings. Additionally, Prism will complete the construction of a parking garage to serve both 100 Metro Blvd. and future tenants at the adjacent, 15-story 200 Metro Blvd. tower in time for Ralph Lauren’s anticipated move-in.
The diagnostics-information provider has received the go-ahead from the City of Clifton to build a two-story, 250,000 square feet combination lab and office building, as well as a five-story garage with just over 1,000 parking stalls. The parcel is 12.4 acres with the address 1153 Bloomfield Ave. The firm, awarded $55.1 million in state tax incentives for the project, would be performing the first build-to-suit construction at ON3.
Quest will relocate some 754 jobs from its Teterboro location and provide New Jersey an additional 384 jobs, according to the Economic Development Authority.
Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit us at www.eisai.com/US and follow us on Twitter and LinkedIn.
At Eisai Inc., human health care (hhc) is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs.
HACKENSACK MERIDIAN HEALTH CENTER FOR DISCOVERY AND INNOVATION
Expanding its presence at ON3, Hackensack Meridian Health signed a long-term lease at 111 Ideation Way in 2018, and established its Hackensack Meridian Health Center for Discovery and Innovation (CDI) at the building.
The CDI is a ground-breaking, academic-based center that rapidly harnesses innovations arising from a new renaissance in biomedical sciences to restore patient health. The CDI is dedicated to preventing, reducing and curing acute and chronic diseases related to cancer, infectious diseases and other life-threatening and debilitating conditions. In pursuing this mission, CDI seeks to address some of society’s critical goals, from improving health and wellness to reducing health care costs and overcoming global health disparities.
The CDI’s science is guided by the nature of the diseases afflicting patients. A strong partnership with the Hackensack Meridian School of Medicine and Hackensack Meridian Health’s 17 network hospitals enables researchers and clinicians to work closely to maximize new age biomedical sciences for optimal patient care. The CDI benefits from multiple NIH (National Institutes of Health) grants for research and discovery. To learn more, visit hmh-cdi.org.
Y-mAbs Therapeutics is a late-stage clinical biopharmaceutical company focused on the development and commercialization of antibody-based therapeutic products for the treatment of cancer. Y-mAbs’ mission is to become the world leader in developing better and safer products to treat challenging pediatric cancers and unmet adult medical needs. Y-mAbs has commercialized the first FDA-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.
Y-mAbs has a broad product pipeline that includes product candidates against a range of targets. The company’s expanding portfolio features accelerated FDA approval for naxitamab and pivotal-stage investigational omburtamab. Both antibodies were granted breakthrough therapy designation to expedite their development to treat a variety of tumors. Learn more at ymabs.com.